A long term safety study to evaluate the Trabodenoson monotherapy in patients with ocular hypertension or open angle glaucoma

Trial Profile

A long term safety study to evaluate the Trabodenoson monotherapy in patients with ocular hypertension or open angle glaucoma

Planning
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Trabodenoson (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Inotek Pharmaceuticals
  • Most Recent Events

    • 31 Mar 2015 Inotek Pharmaceuticals expects to begin this trial in early 2017.If the primary objectives of phase III program are met, then Inotek Pharmaceuticals will submit a NDA to the US FDA for marketing approval of Trabodenoson for the treatment of glaucoma in the USA and plans to submit a MAA in Europe subsequently, according to the company SEC filing report 10-K 2014.
    • 31 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top